This company seems to have been delisted
Reason: Acquired by Sobi
Last recorded trade on: August 25, 2023
Source: https://finance.yahoo.com/news/sobi-completes-acquisition-cti-biopharma-134500966.html
Reason: Acquired by Sobi
Last recorded trade on: August 25, 2023
Source: https://finance.yahoo.com/news/sobi-completes-acquisition-cti-biopharma-134500966.html
CTI BioPharma
CTIC
HK$71.35
Share price
0.00%
Change (1 day)
31.48%
Change (1 year)
Categories
CTI BioPharma (CTIC) - Total debt
Total debt on the balance sheet as of March 2023 : HK$0.38 Billion
According to CTI BioPharma 's latest financial reports the company's total debt is HK$0.38 Billion. A company’s total debt is the sum of all current and non-current debts.
CTI BioPharma - Total debt on balance sheet (from 1997 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | HK$0.39 B | -0.98% |
| 2021-12-31 | HK$0.39 B | 867.69% |
| 2020-12-31 | HK$40.73 M | -57.33% |
| 2019-12-31 | HK$95.48 M | -13.4% |
| 2018-12-31 | HK$0.11 B | 0.66% |
| 2017-12-31 | HK$0.10 B | -26.66% |
| 2016-12-31 | HK$0.14 B | -65.97% |
| 2015-12-31 | HK$0.43 B | 225.65% |
| 2014-12-31 | HK$0.13 B | 30.62% |
| 2013-12-31 | HK$0.10 B | |
| 2012-12-31 | N/A | |
| 2010-12-31 | HK$0.21 B | -56.62% |
| 2009-12-31 | HK$0.50 B | -55.12% |
| 2008-12-31 | HK$1.12 B | -2.4% |
| 2007-12-31 | HK$1.15 B | -10.83% |
| 2006-12-31 | HK$1.29 B | -28.42% |
| 2005-12-31 | HK$1.81 B | 18.61% |
| 2004-12-31 | HK$1.52 B | 2.7% |
| 2003-12-31 | HK$1.48 B | 62.51% |
| 2002-12-31 | HK$0.91 B | -34.28% |
| 2001-12-31 | HK$1.39 B | 6873.97% |
| 2000-12-31 | HK$19.96 M | -32.37% |
| 1999-12-31 | HK$29.52 M | -25.29% |
| 1998-12-31 | HK$39.51 M | 34.18% |
| 1997-12-31 | HK$29.44 M | 18.98% |
| 1996-12-31 | HK$24.75 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | HK$450.42 B | 117,255.56% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | HK$402.21 B | 104,693.95% | 🇺🇸 USA |
 Incyte INCY | HK$0.33 B | -11.81% | 🇺🇸 USA |
 Baxter BAX | HK$80.92 B | 20,983.96% | 🇺🇸 USA |
 Eli Lilly LLY | HK$302.33 B | 78,672.68% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | HK$132.96 B | 34,543.62% | 🇮🇱 Israel |
 Novartis NVS | HK$245.46 B | 63,853.37% | 🇨🇭 Switzerland |